Table 3 MAIC of efficacy and safety for safinamide versus rasagiline.

From: Comparing the efficacy and safety of safinamide with rasagiline in China Parkinson’s disease patients with a matching adjusted indirect comparison

 

Safinamide vs. placebo

Rasagiline vs. placebo

Measure

Safinamide vs. rasagiline

LSM (SE)

LSM (SE)

Efficacy outcomes

 Off-time

− 1.2 (0.28) **

− 0.5 (0.22) *

MD (95% CI)

− 0.7 (− 1.40, − 0.02) *

 UPDRS III (on phase)

− 4.5 (0.96) **

− 1.6 (0.74) *

MD (95% CI)

− 2.9 (− 5.28, − 0.52) *

 PDQ-39 summary index score

− 4.0 (1.08) **

− 1.8 (1.12)

MD (95% CI)

− 2.2 (− 5.26, 0.84)

 Activities of daily living score

− 6.7 (1.74) **

− 6.1 (1.76) **

MD (95% CI)

− 0.6 (− 5.44, 4.24)

 Emotional well-being score

− 5.6 (1.69) **

− 2.4 (2.00)

MD (95% CI)

− 3.2 (− 8.36, 1.90)

 Mobility score

− 6.0 (1.57) **

− 2.5 (1.56)

MD (95% CI)

− 3.5 (− 7.84, 0.84)

 Stigma score

− 6.4 (1.99) **

− 2.5 (1.92)

MD (95% CI)

− 3.9 (− 9.27, 1.57)

Safety outcomes

 AEs

1.9 (0.26)

1.1 (0.23)

OR (95% CI)

1.6 (0.83, 3.19)

 SAEs

1.5 (0.62)

1.4 (0.60)

OR (95% CI)

1.1 (0.21, 6.14)

 Discontinuations due to AEs

0.8 (0.52)

1.2 (0.62)

OR (95% CI)

0.7 (0.14, 3.28)

  1. *p < 0.05, **p < 0.01.
  2. LSM least-squares mean, SE standard error, MD mean difference, UPDRS unified Parkinsons’ disease rating scale, PDQ-39 39-Item Parkinson’s Disease Questionnaire, AEs adverse events, SAEs serious adverse events, MAIC matching-adjusted indirect comparison, MD mean difference, OR odds ratio, CI confidence interval.
Back to article page